The stock has a 36-month beta value of 1.42. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
On November 21, 2024, the average trading volume of BDRX was 161.31K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BDRX) stock’s latest price update
Biodexa Pharmaceuticals Plc ADR (NASDAQ: BDRX)’s stock price has plunge by 66.75relation to previous closing price of 3.85. Nevertheless, the company has seen a 32.10% surge in its stock price over the last five trading sessions. accesswire.com reported 2024-11-21 that CARDIFF, UK / ACCESSWIRE / November 21, 2024 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical-stage biopharmaceutical company focused on developing treatments for unmet medical needs, has made significant progress in transforming itself from a drug delivery innovator to a therapeutics company with a focus on drugs to fight diabetes and cancer. Biodexa’s strategy is not based on discovering new medicines; rather it looks to reduce the risk of failure in the clinic by re-purposing molecules with proven safety records for new indications.
BDRX’s Market Performance
Biodexa Pharmaceuticals Plc ADR (BDRX) has seen a 32.10% rise in stock performance for the week, with a -9.19% decline in the past month and a -58.93% plunge in the past quarter. The volatility ratio for the week is 12.43%, and the volatility levels for the past 30 days are at 10.36% for BDRX. The simple moving average for the past 20 days is 20.35% for BDRX’s stock, with a -67.84% simple moving average for the past 200 days.
Analysts’ Opinion of BDRX
Many brokerage firms have already submitted their reports for BDRX stocks, with Ladenburg Thalmann repeating the rating for BDRX by listing it as a “Buy.” The predicted price for BDRX in the upcoming period, according to Ladenburg Thalmann is $8 based on the research report published on February 08, 2024 of the current year 2024.
BDRX Trading at 2.16% from the 50-Day Moving Average
After a stumble in the market that brought BDRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.09% of loss for the given period.
Volatility was left at 10.36%, however, over the last 30 days, the volatility rate increased by 12.43%, as shares sank -29.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -52.00% lower at present.
During the last 5 trading sessions, BDRX fell by -3.70%, which changed the moving average for the period of 200-days by -86.13% in comparison to the 20-day moving average, which settled at $5.25. In addition, Biodexa Pharmaceuticals Plc ADR saw -90.42% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BDRX
Current profitability levels for the company are sitting at:
- -87.81 for the present operating margin
- -52.49 for the gross margin
The net margin for Biodexa Pharmaceuticals Plc ADR stands at -82.16. The total capital return value is set at -0.69. Equity return is now at value -96.61, with -61.80 for asset returns.
Currently, EBITDA for the company is -6.46 million with net debt to EBITDA at 0.73. When we switch over and look at the enterprise to sales, we see a ratio of -24.58. The receivables turnover for the company is 0.04for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.16.
Conclusion
To sum up, Biodexa Pharmaceuticals Plc ADR (BDRX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
